NCT00439673View on ClinicalTrials.gov

PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS

PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions
Myelodysplastic Syndromes
Interventions
DRUG

5-Azacytidine

DRUG

Valproic Acid

DRUG

ATRA

Trial Locations (7)

Unknown

USL 8 di Arezzo, Arezzo

Azienda Ospedaliera S. G. Moscati, Avellino

Università degli studi di Bari, Bari

Istituto ematologia e oncologia medica L.A. Seragnoli, Bologna

Ospedale Reg. A di Summa, Brindisi

Ospedale A. Businco, Cagliari

Università degli studi di Roma La Cattolica, Roma

All Listed Sponsors
lead

Gruppo Italiano Malattie EMatologiche dell'Adulto

OTHER

NCT00439673 - PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS | Biotech Hunter | Biotech Hunter